Evaluation of the optimal number of lesions needed for tumor evaluation using the response evaluation criteria in solid tumors: a north central cancer treatment group investigation.
PURPOSE In February 2000, the criteria for measuring tumor shrinkage as an indicator of antitumor activity were redefined by the Response Evaluation Criteria in Solid Tumors (RECIST). This resulted in simplifying bidimensional to unidimensional measurement of lesions. Under RECIST, all lesions, up to 10, must be measured. Scanning and measuring multiple lesions is costly, time-consuming, and a disincentive to participation in clinical trials. We investigated whether fewer than 10 lesions can be measured without compromising the accuracy of assessing a regimen's activity. PATIENTS AND METHODS Thirty-two North Central Cancer Treatment Group trials including 2,374 patients were analyzed. Twelve studies were conducted before RECIST; 20 were conducted post-RECIST. Agreement between objective status by cycle, confirmed response, overall response rate, and time to progression (TTP) was evaluated based on all 10 versus the largest one through five lesions. Results The median number of lesions reported on RECIST trials did not differ from pre-RECIST trials (median = 2.0). One lesion at baseline was reported in 49% of patients, two lesions in 28% of patients, three lesions in 12% of patients, four lesions in 6% of patients, and five lesions in 5% of patients in post-RECIST trials. Utilizing the largest two lesions produced excellent concordance with that using all lesions for all end points. In no trial did the overall response rate differ by more than 3% when two versus all lesions were considered. Evaluating more than two lesions did not significantly improve agreement. CONCLUSION Based on these trials, the assessment of more than two lesions did not alter the conclusions regarding a treatment's efficacy as judged by response rate or TTP.
Hillman
Shauna L
SL
Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA. hillman.shauna@mayo.edu
An
Ming-Wen
MW
O'Connell
Michael J
MJ
Goldberg
Richard M
RM
Schaefer
Paul
P
Buckner
Jan C
JC
Sargent
Daniel J
DJ
D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D003952:Diagnostic Imaging; D018450:Disease Progression; D006801:Humans; D009369:Neoplasms / Q000473:pathology* / Q000628:therapy*; D016896:Treatment Outcome